文献速递造血干细胞移植与细胞治疗白血病

儿童CD19-CAR T细胞患者神经毒性期间GFAP和NfL从高基线水平升高

GFAP and NfL increase during neurotoxicity from high baseline levels in pediatric CD19-CAR T-cell patients.
PubMed 文献 · Blood Adv · 2023-01-01

该研究在3个接受CD19或CD19/CD22靶向CAR T细胞的儿童队列中,于预处理前及输注后第7至10天检测脑脊液GFAP(cGFAP)、脑脊液NfL(cNfL)和血清NfL(sNfL)。接受CD19靶向CAR T细胞的患者在≥1级ICANS期间cGFAP和cNfL升高,而接受CD19/CD22靶向者未升高,sNfL在ICANS期间未升高。预处理前三种标志物均不能预测后续ICANS。

要点

  • 接受CD19靶向CAR T细胞的患儿在≥1级ICANS期间cGFAP和cNfL升高。
  • 接受CD19/CD22靶向CAR T细胞的患儿在ICANS期间cGFAP和cNfL未升高。
  • 预处理前cGFAP、cNfL和sNfL水平均不能预测后续ICANS风险。

核心结论

  • cGFAP和cNfL可能是有用的生物标志物,用于测量儿童ICANS期间中枢神经系统损伤的严重程度。
  • 基线cGFAP、cNfL和sNfL水平升高可能反映既往治疗对中枢和周围神经系统的累积损伤。
  • CAR T细胞输注前三种生物标志物中任何一种的水平均不能预测ICANS风险。

研究设计与样本

  • 研究在3个接受CD19或CD19/CD22靶向CAR T细胞治疗的儿童队列中,于预处理前和CAR T细胞输注后第7至10天测量cGFAP、cNfL和sNfL水平。

主要发现

  • 接受CD19靶向CAR T细胞的患者在≥1级ICANS期间cGFAP和cNfL水平升高,而接受CD19/CD22靶向CAR T细胞的患者未升高。
  • sNfL水平在ICANS期间未升高。
  • 预处理前(淋巴细胞清除前)cGFAP、cNfL和sNfL水平不能预测后续ICANS。
  • 基线cGFAP水平升高与移植史相关。
  • 有中枢神经系统放疗史的患者cNfL水平更高,基线sNfL水平升高与周围神经病变史相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

There is a need for biomarkers to predict and measure the severity of immune effector cell-associated neurotoxicity syndrome (ICANS). Glial fibrillary acidic protein (GFAP) and neurofilament light chain (NfL) are well-validated biomarkers of astroglial and neuronal injury, respectively. We hypothesized that pretreatment GFAP and NfL levels can predict the risk of subsequent ICANS and that increases in GFAP and NfL levels during treatment reflect ICANS severity. We measured cerebrospinal fluid GFAP (cGFAP) and NfL (cNfL) along with serum NfL (sNfL) levels at pretreatment and day 7 to 10 after chimeric antigen receptor (CAR) T-cell infusion in 3 pediatric cohorts treated with CD19- or CD19/CD22-directed CAR T cells. cGFAP and cNfL levels increased during grade ≥1 ICANS in patients treated with CD19-directed CAR T cells but not in those who received CD19/CD22-directed CAR T cells. The sNfL levels did not increase during ICANS. Prelymphodepletion cGFAP, cNfL, and sNfL levels were not predictive of subsequent ICANS. Elevated baseline cGFAP levels were associated with a history of transplantation. Patients with prior central nervous system (CNS) radiation had higher cNfL levels, and elevated baseline sNfL levels were associated with a history of peripheral neuropathy. Thus, cGFAP and cNfL may be useful biomarkers for measuring the severity of CNS injury during ICANS in children. Elevated baseline levels of cGFAP, cNfL, and sNfL likely reflect the cumulative injury to the central and peripheral nervous systems from prior treatment. However, levels of any of the 3 biomarkers before CAR T-cell infusion did not predict the risk of ICANS.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Gust J, Rawlings-Rhea SD, Wilson AL, et al. GFAP and NfL increase during neurotoxicity from high baseline levels in pediatric CD19-CAR T-cell patients. Blood Adv. 2023. PMID: 36006611. doi:10.1182/bloodadvances.2022008119

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。